{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T18:26:00Z","timestamp":1778955960018,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1053\/j.seminoncol.2018.09.002","type":"journal-article","created":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T00:13:50Z","timestamp":1540080830000},"page":"181-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Cancer immunotherapy-associated hypophysitis"],"prefix":"10.1053","volume":"45","author":[{"given":"Cinzia","family":"Solinas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3090-8541","authenticated-orcid":false,"given":"Michele","family":"Porcu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pushpamali","family":"De Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Musi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6598-9161","authenticated-orcid":false,"given":"Sandrine","family":"Aspeslagh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Scartozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1150-1295","authenticated-orcid":false,"given":"Karen","family":"Willard-Gallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Saba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2018.09.002_bib0001","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1634\/theoncologist.2016-0055","article-title":"Management of adverse events following treatment with anti-programmed death-1 agents","volume":"21","author":"Weber","year":"2016","journal-title":"Oncologist"},{"issue":"21","key":"10.1053\/j.seminoncol.2018.09.002_bib0002","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1053\/j.seminoncol.2018.09.002_bib0003","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.09.002_bib0004","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1530\/EJE-17-0810","article-title":"The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpointinhibitors for metastatic melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.09.002_bib0005","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1148\/rg.352140121","article-title":"Cancer immunotherapy: imaging assessment of novel treatment response patterns and immune-related adverse events","volume":"35","author":"Kwak","year":"2015","journal-title":"Radiographics"},{"issue":"suppl_4","key":"10.1053\/j.seminoncol.2018.09.002_bib0006","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1053\/j.seminoncol.2018.09.002_bib0007","doi-asserted-by":"crossref","first-page":"T331","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"10.1053\/j.seminoncol.2018.09.002_bib0008","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1053\/j.seminoncol.2018.09.002_bib0009","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.09.002_bib0010","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in previously untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1053\/j.seminoncol.2018.09.002_bib0011","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol."},{"issue":"19","key":"10.1053\/j.seminoncol.2018.09.002_bib0012","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.seminoncol.2018.09.002_bib0013","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1053\/j.seminoncol.2018.09.002_bib0014","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1053\/j.seminoncol.2018.09.002_bib0015","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.seminoncol.2018.09.002_bib0016","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminoncol.2018.09.002_bib0017","series-title":"Textbook of medical physiology","author":"Guyton","year":"2006"},{"issue":"5","key":"10.1053\/j.seminoncol.2018.09.002_bib0018","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/er.2004-0011","article-title":"Autoimmune hypophysitis","volume":"26","author":"Caturegli","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1053\/j.seminoncol.2018.09.002_bib0019","article-title":"Is autoimmunity the Achilles' heel of cancer immunotherapy?","author":"June","year":"2017","journal-title":"Nat Med"},{"issue":"230","key":"10.1053\/j.seminoncol.2018.09.002_bib0020","doi-asserted-by":"crossref","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"issue":"12","key":"10.1053\/j.seminoncol.2018.09.002_bib0021","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic t-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"10.1053\/j.seminoncol.2018.09.002_bib0022","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4137\/CMED.S22469","article-title":"Immune checkpoint inhibitor therapy associated hypophysitis","volume":"8","author":"Mahzari","year":"2015","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.09.002_bib0023","doi-asserted-by":"crossref","first-page":"R153","DOI":"10.1530\/EJE-13-0434","article-title":"Endocrine side-effects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses","volume":"169","author":"Torino","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1053\/j.seminoncol.2018.09.002_bib0024","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"issue":"15","key":"10.1053\/j.seminoncol.2018.09.002_bib0025","article-title":"Safety profile of nivolumab (NIVO) in patients (pts) with advanced melanoma (MEL): A pooled analysis","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1053\/j.seminoncol.2018.09.002_bib0026","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminoncol.2018.09.002_bib0027","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/CMR.0000000000000405","article-title":"Transient pituitary ACTH-dependent Cushing syndrome caused by an immune checkpoint inhibitor combination","volume":"27","author":"Lupu","year":"2017","journal-title":"Melanoma Res."},{"issue":"1","key":"10.1053\/j.seminoncol.2018.09.002_bib0028","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.09.002_bib0029","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","article-title":"Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights","volume":"19","author":"Faje","year":"2016","journal-title":"Pituitary"},{"issue":"9","key":"10.1053\/j.seminoncol.2018.09.002_bib0030","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3174\/ajnr.A1623","article-title":"Ipilimumab-induced hypophysitis: MR imaging findings","volume":"30","author":"Carpenter","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.09.002_bib0031","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-12-0167","article-title":"Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review","volume":"167","author":"Juszczak","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1053\/j.seminoncol.2018.09.002_bib0032","doi-asserted-by":"crossref","first-page":"W223","DOI":"10.2214\/AJR.05.2027","article-title":"Anatomic and pathologic spectrum of pituitary infundibulum lesions","volume":"188","author":"Hamilton","year":"2007","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1053\/j.seminoncol.2018.09.002_bib0033","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.nic.2005.02.007","article-title":"Imaging the sella and parasellar region","volume":"15","author":"Pisaneschi","year":"2005","journal-title":"Neuroimaging Clin N Am"},{"key":"10.1053\/j.seminoncol.2018.09.002_bib0034","series-title":"Sellar and Parasellar Tumors, Diagnosis, Treatments, and Outcomes","author":"Laws","year":"2011"},{"key":"10.1053\/j.seminoncol.2018.09.002_bib0035","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ctrv.2017.06.002","article-title":"Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management","volume":"58","author":"Sznol","year":"2017","journal-title":"Cancer Treat Rev"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775418301064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775418301064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:54:10Z","timestamp":1758804850000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775418301064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0093775418301064"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2018.09.002","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer immunotherapy-associated hypophysitis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminoncol.2018.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}